Here’s what star stock picker Cathie Wood bought after the market correction!

Our writer takes a look at what Cathie Wood, the CEO and co-founder of ARK Invest, has been buying this week.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Cathie Wood is known as a star stock picker and is the CEO of Ark Invest (NYSEMKT:ARKK), an investment management firm that she founded.

After last week’s sell-off, Ark Invest started this week by purchasing shares several companies, including the three listed below.

All three are considerably down on their 2021 highs, and were pushed lower last week on the back of higher than expected US inflation data.

So, what was she buying? Wood added to her existing exchange-traded fund stakes in CRISPR Therapeutics (NYSE:CRSP), Invitae Corporation (NYSE:NVTA), and Pacific Biosciences (NASDAQ:PACB).

CRISPR Therapeutics

CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases. The firm has a market cap of around $4.28bn, but is down 57.1% over the past 12 months.

CRISPR (an acronym for clustered regularly interspaced short palindromic repeats) is a technology that can be used to edit genes. It’s considered more efficient than other technologies out there.

CRISPR plans on submitting its candidate treatment for blood disorders for regulatory approval at the end of this year. The company has also partnered with Vertex Pharmaceuticals, and reported positive clinical trial data with candidate products in sickle cell disease and beta thalassemia.

It could be a big winner, however, it will carry a lot of risk until it gains regulatory approval. The business itself has noted caution on the part of regulators with regards to gene therapy treatments.

Invitae Corporation

Invitae stock reached $61 a share last year before collapsing. It now trades for just $2.32. The stock is down 92% over the past year.

The biotechnology company does genetic screening and hopes to bring its product to billions of people. Invitae’s screening looks to highlight whether individuals have higher risk profiles for hereditary cancer and rare genetic diseases, among other illnesses.

Oncology is a major part of the business, accounting for almost two-thirds of its revenue in the first quarter.

The firm is in an interesting position after its stock price crash. It has a market cap of just short of $500m, but had $885 million in cash at the end of the first quarter. However, Invitae doesn’t anticipate being cash flow positive until 2025.

Pacific Biosciences

Pacific Biosciences is a biotech firm that develops and manufactures systems for gene sequencing and real time biological observation.

This stock has also crashed over the past year, from highs of $36 to the current $4.32. The stock is down 84% over the past year.

In 2019, Pacific Biosciences launched its Sequel II genome sequencing system, that offers eight times the data output of its older model. It also brought accuracy in line with traditional sequencing methods.

One issue is that the company is spending almost all of its revenue on development at the moment. Last year, it spent $113m. In 2021, the firm generated $130m in revenue.

On my to-do list

Given Wood’s interest in these stocks, I’ll be taking a closer look myself to see if any of them would be right for my portfolio. Biotechs are a bit new to me, so I’d want to do my research to understand both the risks and opportunities in the field.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has no position in any of the shares mentioned. The Motley Fool UK has recommended CRISPR Therapeutics. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »